Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Seeding the next wave of myeloma drug development

How the Myeloma Investment Fund approaches venture philanthropy and views the future of the myeloma treatment landscape

By Stephen Hansen, Director of Biopharma Intelligence
August 14, 2024 11:46 PM UTC

The Myeloma Investment Fund is putting its own spin on the venture philanthropy model — providing modest amounts of start-up capital, but with a deep knowledge base related to drug development and KOLs that can help newcos develop their myeloma therapies.

The Multiple Myeloma Research Foundation (MMRF) launched the Myeloma Investment Fund (MIF) in 2019 with $50 million to invest in start-up and early-stage companies that have a therapeutic program with the potential to treat MM. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Dynamic Cell Therapies Inc.

Envisagenics Inc.

Multiple Myeloma Research Foundation (MMRF)

Nammi Therapeutics Inc.

Neximmune Inc.